Potent growth-inhibitory effect of TRAIL therapy mediated by double-regulated oncolytic adenovirus on osteosarcoma

Area of Science:

• Oncolytic virotherapy
• Gene therapy for bone cancers
• Molecular mechanisms of osteosarcoma

Background:

• Osteosarcoma (OS) is a significant health concern, particularly for young individuals.
• Effective gene therapy for OS is hindered by insufficient gene expression from current vectors.
• Understanding OS molecular etiology is crucial for developing targeted therapeutic strategies.

Purpose of the Study:

• To develop a novel oncolytic adenoviral vector (OAT) for enhanced gene expression in OS.
• To evaluate the efficacy and biosafety of OAT-mediated gene delivery in osteosarcoma.
• To investigate the potential of OAT-based gene therapy for clinical application in OS.

Main Methods:

• Development of a replication-selective oncolytic adenoviral vector (OAT).
• Transduction of osteosarcoma cells with OAT-mediated TRAIL expression.
• In vitro and in vivo assessment of OAT-TRAIL efficacy and biosafety compared to a control vector (Ad5).

Main Results:

• OAT demonstrated significantly higher TRAIL expression in OS cells compared to the Ad5 vector.
• OAT-TRAIL treatment exhibited enhanced antitumor capacity in osteosarcoma cells, both in vitro and in vivo.
• OAT-TRAIL showed limited replication, TRAIL expression, and growth inhibition in normal cells, indicating high biosafety.

Conclusions:

• The novel oncolytic adenoviral vector (OAT) is an efficient and promising tool for osteosarcoma gene therapy.
• OAT enables enhanced gene expression and antitumor activity specifically in osteosarcoma cells.
• The demonstrated biosafety profile of OAT supports its potential for clinical translation in OS treatment.